- In patients with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL), early treatment failure with intensive first-line (1L) therapy independently predicted inferior outcomes with platinum-based (2L) immunochemotherapy.
Why this matters
- This may be the largest study reporting outcomes in this setting after failure with intensive 1L therapy.
- Study to investigate outcomes in 195 patients with relapsed/refractory DLBCL or HGBL treated with salvage platinum-based immunochemotherapy after failure of intensive 1L therapy.
- Frontline regimens:
- 82% received dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R);
- 16% received rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and cytarabine (R-HyperCVAD); and
- 2% received rituximab, cyclophosphamide, vincristine, doxorubicin, and high-dose methotrexate alternating with ifosfamide, etoposide, and cytarabine (R-CODOX-M/IVAC).
- Funding: None disclosed.
- 43% overall response to 2L therapy.
- 3 (95% CI, 2.4-4) months median PFS.
- 8 (95% CI, 6-10.1) months median OS.
- In multivariate analysis, patients with early treatment failure (primary refractory/relapse
- Disease progression: HR=2.43; 95% CI, 1.11-5.31; P=.024.
- Death: HR=5.90; 95% CI, 2.02-17.21; P=.001.
- Retrospective data.